Skip to content

Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017

Published: 07:00 CEST 08-05-2017 /GlobeNewswire /Source: Targovax ASA / : TRVX /ISIN: NO0010689326

Targovax ASA: Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017

Oslo, Norway, 8 May 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will be hosting Capital Markets Updates in Oslo on Thursday 8 June and in London on Monday 26 June 2017.

The meetings, which will be open to analysts, brokers, investors and press, will include presentations from world leading experts on resected pancreatic cancer patients, as well as from Targovax’s senior management team. Presentations are expected to cover the following areas:


  • Introduction to Targovax
  • Technology and clinical trials
  • A clinician’s view on pancreatic cancer and current treatment options
  • Overview of TG01 data from the Phase I/II resected pancreatic cancer trial presented at ASCO, presented by one of the principal investigators


A formal program will be announced nearer the time.

To register for the Oslo event, please contact

To register for the London event, please contact



 For further information, please contact

Renate Birkeli, IR

Phone: +47 922 61 624



Media and IR enquires:

Jan Petter Stiff – Crux Advisers (Norway)

Phone: +47 995 13 891



Julia Phillips/Simon Conway – FTI Consulting (International)

Phone: +44 20 3727 1000




About Targovax


Arming the patient’s immune system to fight cancer


Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.


The Company’s development pipeline is based on two novel proprietary platforms:


The first platform, ONCOS, uses oncolytic viruses, an emerging class of biological therapy. ONCOS exclusively uses an adenovirus that has been engineered to be an immune activator that selectively target cancer cells. In phase I it has shown to immune activate at lesional level which was associated with clinical benefit. We expect proof of concept data for this platform in 2017 from a clinical trial of lead product ONCOS-102 in patients with refractory malignant melanoma.


The second platform, TG peptides (TG), solely targets tumors that express mutated forms of the RAS protein. Mutations to this protein are common in many cancers and are known to drive aggressive disease progression and treatment resistance. There is a high unmet medical need for therapies that are effective against tumors that express these mutations. The TG platform’s therapeutic potential stems from its ability to enable a patient’s immune system to identify and then destroy tumors bearing any RAS mutations. In early 2017, key proof of concept data for the TG platform from a clinical trial of TG01 in resected pancreatic cancer patients showed encouraging overall survival and will give guidance for the future clinical development of this platform.


Targovax’s development pipeline has three novel therapeutic candidates in clinical development covering six indications.


Both platforms are protected by an extensive portfolio of IP and know-how and have the potential to yield multiple product candidates in a cost-effective manner. Additionally, we have other products in early stages of development.


In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Source: GlobeNewswire /Source: Targovax ASA